132584-17-9

Basic information

• Product Name: ethyl 2-hydroxy-2-(4-phenoxyphenyl)propanoate
• Synonyms: 132584-17-9; 2OVXQ1& R DOR; 429-220-9; Ethyl 2-(4-phenoxyphenyl)lactate; Ethyl 2-hydroxy-2-(4-phenoxyphenyl)propionate; Ethyl α-hydroxy-α-methyl-4-phenoxybenzeneacetate
• CAS NO: 132584-17-9
• Molecular Formula: C₁₇H₁₈O₄
• Molecular Weight: 286.3224
• EINECS: 429-220-9
• Mol File: 132584-17-9.mol

Chemical Properties

• Boiling Point: 413.965°C at 760 mmHg
• Flash Point: 147.649°C
• Density: 1.172g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.561
• CAS DataBase Reference: ethyl 2-hydroxy-2-(4-phenoxyphenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-hydroxy-2-(4-phenoxyphenyl)propanoate(132584-17-9)
• EPA Substance Registry System: ethyl 2-hydroxy-2-(4-phenoxyphenyl)propanoate(132584-17-9)

Safety Data

• Hazardous Substances Data: 132584-17-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-hydroxy-2-(4-phenoxyphenyl)propanoate is used as an intermediate in the synthesis of pharmaceuticals for its anti-inflammatory and analgesic properties. It aids in the development of medication formulations that can provide relief from inflammation and pain.
Used in Agrochemical Industry:
Ethyl 2-hydroxy-2-(4-phenoxyphenyl)propanoate is used as a precursor in the synthesis of agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Research and Development:
Ethyl 2-hydroxy-2-(4-phenoxyphenyl)propanoate is used as a research compound for exploring its potential in the development of new therapeutic agents for various medical conditions. Its properties are being studied to identify its effectiveness in treating different health issues.

Upstream product

• 617-35-6 2-oxo-propionic acid ethyl ester 
• 101-55-3 4-Bromodiphenyl ether 
• 101-84-8 diphenylether 

Downstream Products

• 131807-57-3 famoxadone 
• 334700-65-1 ethyl 2-(p-nitrophenoxycarbonyloxy)-2-(4-phenoxyphenyl)propionate 
• 1322705-24-7 C₂₄H₂₂N₂O₄ 
• 1322705-21-4 C₂₃H₂₀N₂O₅ 
• 1322705-20-3 C₂₂H₁₇ClN₂O₄ 
• 1322705-19-0 C₂₃H₂₀N₂O₄ 
• 1322705-18-9 cyanofamoxadone 
• 1322705-15-6 C₂₃H₁₇F₃N₂O₄ 
• 1322705-14-5 C₂₂H₁₇BrN₂O₄ 
• 1322705-13-4 C₂₄H₂₂N₂O₄ 
• 1322705-12-3 C₂₂H₁₆BrFN₂O₄ 
• 1322705-11-2 5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)oxazolidine-2,4-dione 

Relevant articles and documents

Synthetic method of lactate derivative as well as product and application thereof

The invention provides a synthetic method of a lactate derivative, a product synthesized by the synthetic method and an application of the product. The synthetic route of the synthetic method is as shown in the specification. A compound IV, a compound III and alkali as a catalyst are added into a solvent, and then Lewis acid is added for reaction, so that the lactate derivative I is prepared. According to the synthetic method of the lactate derivative provided by the invention, the target product is obtained just through a one-step chemical reaction, and the synthetic method is mild in reaction conditions, simple in operation, relatively high in yield and relatively low in cost; therefore, the synthetic method is beneficial for large-scale industrial production, and a foundation can be laid for subsequent production of various pesticides or medicine products represented by pyrethroids pesticides; and therefore, the synthetic method as well as the product and the application thereof have a good application prospect and market potential.

Design, syntheses, and kinetic evaluation of 3-(phenylamino)oxazolidine-2, 4-diones as potent cytochrome bc1 complex inhibitors

The cytochrome bc1 complex (EC 1.10.2.2, bc1) is one of the most promising targets for new drugs and agricultural fungicides. Among the existing bc1 complex inhibitors specifically binding to the Qo site, oxazolidinedione derivatives have attracted great attention. With the aim to understand the substituent effects of oxazolidinedione derivatives on the inhibition activity against the bc1 complex, a series of new oxazolidinedione derivatives were designed, synthesized, and biologically evaluated. The further inhibitory kinetics studies against porcine succinate-cytochrome c reductase (SCR) revealed that the representative compound 8d and famoxadone are both non-competitive inhibitors with respect to the substrate cytochrome c, but competitive inhibitors with respect to substrate decylubiquinol (DBH2). In addition, compound 8d and famoxadone showed, respectively, 35-fold and 15-fold greater inhibitory activity against the porcine SCR than the porcine bc1 complex, indicating that these two inhibitors not only inhibited the activity of the bc1 complex, but possibly affect the interaction between the complex II and the bc 1 complex. To our knowledge, this is the first report that famoxadone and its analogs have effects on the interaction between the complex II and the bc1 complex.

Fungicidal oxazolidinones

Compounds for an methods of controlling plant diseases using thiooxazolidinones, oxazolidindiones and agriculturally suitable compositions containing them are disclosed.